These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 7541571

  • 21. [Hormone therapy for prostate cancer].
    Théodore C.
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [Abstract] [Full Text] [Related]

  • 22. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 23. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Vopr Onkol; 1998 Jul 01; 44(5):537-40. PubMed ID: 9884710
    [Abstract] [Full Text] [Related]

  • 24. Hormone therapy of advanced prostate cancer: where we stand today.
    Crawford ED, Nabors W.
    Oncology (Williston Park); 1991 Jan 01; 5(1):21-30; discussion 30, 32, 37. PubMed ID: 1828686
    [Abstract] [Full Text] [Related]

  • 25. [Conservative therapy of prostate cancer].
    Leitenberger A, Altwein JE.
    Fortschr Med; 1991 Sep 30; 109(28):563-7. PubMed ID: 1721888
    [Abstract] [Full Text] [Related]

  • 26. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H, Messing EM, Chang C.
    Prostate; 2004 Dec 01; 61(4):332-53. PubMed ID: 15389811
    [Abstract] [Full Text] [Related]

  • 27. Gn-RH agonists in the treatment of prostatic carcinoma.
    Vacher P.
    Biomed Pharmacother; 1995 Dec 01; 49(7-8):325-31. PubMed ID: 8562857
    [Abstract] [Full Text] [Related]

  • 28. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T.
    J Urol; 2000 Dec 01; 164(6):1992-5. PubMed ID: 11061898
    [Abstract] [Full Text] [Related]

  • 29. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 30. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 31. Maximal androgen blockade versus total androgen suppression.
    Dumez H, Van Poppel H, Baert L, Paridaens R.
    Acta Urol Belg; 1997 Mar 01; 65(1):49-54. PubMed ID: 9175283
    [Abstract] [Full Text] [Related]

  • 32. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY.
    J Pathol; 2005 Jun 01; 206(2):205-13. PubMed ID: 15818594
    [Abstract] [Full Text] [Related]

  • 33. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F, Dupont A, Belanger A.
    Important Adv Oncol; 1985 Jun 01; ():193-217. PubMed ID: 3916740
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of advanced prostatic cancer.
    Sogani PC, Fair WR.
    Urol Clin North Am; 1987 May 01; 14(2):353-71. PubMed ID: 2953100
    [Abstract] [Full Text] [Related]

  • 35. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A, Ruutu M, Aro J, Rannikko S, Salo J.
    Ann Chir Gynaecol; 1999 May 01; 88(1):18-21. PubMed ID: 10230677
    [Abstract] [Full Text] [Related]

  • 36. Endocrine therapy for prostate cancer.
    Sagalowsky AI.
    Spec Top Endocrinol Metab; 1985 May 01; 7():101-29. PubMed ID: 3914094
    [Abstract] [Full Text] [Related]

  • 37. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ.
    Br J Cancer; 1999 Jan 01; 79(1):146-55. PubMed ID: 10408706
    [Abstract] [Full Text] [Related]

  • 38. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 39. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 May 15; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 40. Treatment of advanced prostate cancer.
    Lynch JH.
    J Fam Pract; 1993 Nov 15; 37(5):488-94. PubMed ID: 7693859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.